Pfizer
Yahoo Finance • yesterday
OPKO Health (OPK) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool. Date Feb. 26, 2026 Call participants Chairman and Chief Executive Officer — Phillip FrostVice Chairman and President — Elias ZerhouniChief Financial Officer — Adam E. LogalIndependent Director and Chief I... Full story
Yahoo Finance • 2 days ago
BC-Most Active Stocks
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Avalon GloboCare Corp. 167,881,021 1.27 0.93 1.0382 +0.53 Curanex Pharma... Full story
Yahoo Finance • 2 days ago
Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas Multiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major globa... Full story
Yahoo Finance • 3 days ago
Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie
Investing.com -- RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development. Pharma stocks trade at about a 25% discount to their 10 year averages despite impr... Full story
Yahoo Finance • 3 days ago
RNA-Based Therapeutics & Vaccines Market is projected to reach USD 2.32 Billion by 2032, growing at a CAGR of 5.50% during 2025–2032, Driven by the Rapid Expansion of mRNA Platform Applications: AnalystView Market Insights
San Francisco, USA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The RNA-based Therapeutics and Vaccines Market was valued at USD 1,285.10 million in 2024 and is projected to reach approximately USD 2,320.54 million by 2032, expanding at a CAGR of... Full story
Yahoo Finance • 4 days ago
Cancer Diagnostics Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033
Dublin, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The "Cancer Diagnostics Market Key Players Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts" report has been added to Rese... Full story
Yahoo Finance • 4 days ago
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory
We came across a bullish thesis on Viking Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.'s share was trading at $29.30 as... Full story
Yahoo Finance • 4 days ago
This Dividend Giant Pfizer Could Turn a Boring Healthcare Allocation Into Serious Income
Pfizer(NYSE: PFE) is one of the world's largest and most respected pharmaceutical companies. That is an important backdrop for dividend investors to consider as they look at the stock's lofty 6.4% dividend yield. For reference, the average... Full story
Yahoo Finance • 4 days ago
Pfizer Pipeline Shifts With Obesity Push And BREAKWATER Cancer Results
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Pfizer (NYSE:PFE) has expanded its obesity drug ambitions with the acquisition of Metsera and more than 20 active clin... Full story
Yahoo Finance • 4 days ago
Pfizer strikes $495M deal for obesity drug rights in China
[Pfizer Canada head office in Kirkland, Quebec, Canada.] JHVEPhoto/iStock Editorial via Getty Images Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) entered a licensing agreement with China’s Sciwind Biosciences for its type 2 diabetes... Full story
Yahoo Finance • 5 days ago
My 5 Favorite Dividend Stocks to Buy Right Now
Does your portfolio need some new income investments? Maybe you're looking for a little more certainty -- and defensiveness -- now that a few too many risky growth stocks are overbought as well as overvalued? Whatever your goal is, here's... Full story
Yahoo Finance • 6 days ago
Notable healthcare headlines for the week: J&J, Masimo and Bayer in focus
Wall Street’s major market averages concluded higher on Friday as investors reacted to the latest PCE inflation report, which came in hotter than expected. The tech-focused Nasdaq Composite ended +0.9%. At the same time, the benchmark S&P... Full story
Yahoo Finance • 8 days ago
Barclays launches U.S. biopharma coverage with four preferred picks
Investing.com -- Barclays launched coverage of U.S. large-cap biopharmaceutical companies, arguing the sector could regain investor attention in an uncertain macro backdrop, while naming Eli Lilly (NYSE:LLY), Merck (NYSE:MRK), Bristol-Myer... Full story
Yahoo Finance • 8 days ago
Moderna sued for violating patent linked to Pfizer/ BioNTech COVID-19 shot
[Moderna To Request Emergency Authorization For Its Vaccine After Positive Trial Results] Maddie Meyer/Getty Images News Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) faces a lawsuit in the U.S. for allegedly infringing patent rig... Full story
Yahoo Finance • 8 days ago
Nicotine Gum Market Analysis Report 2026-2035: A $2.55 Billion Market by 2030 with Pfizer, GlaxoSmithKline, Haleon, Perrigo Co, and Johnson & Johnson Leading
Company Logo The nicotine gum market presents opportunities through rising anti-smoking campaigns, demand for convenient cessation solutions, flavored variants, and online channels. Innovations like lozenges enhance market position. Asia-... Full story
Yahoo Finance • 8 days ago
Tobacco Alternative Gums Analysis Report 2026-2035: A $4.25 Billion Market by 2030 with CVS Health, The Kroger Co., Walgreens Boots Alliance, along with Pfizer, Johnson & Johnson Leading
Company Logo The tobacco alternative gums market presents key opportunities due to rising awareness of smoking risks, innovative nicotine-free products, e-commerce expansion, and growing demand for discreet alternatives. Strategic partner... Full story
Yahoo Finance • 8 days ago
Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash?
Key Points Pfizer has reached a transition point following declines of some of its biggest blockbusters. The pharma giant is paving the way to growth through new products and acquisitions.10 stocks we like better than Pfizer › Pfizer(NYS... Full story
Yahoo Finance • 8 days ago
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as... Full story
Yahoo Finance • 9 days ago
Where is Pfizer Inc. (PFE) Headed?
Pfizer Inc. (NYSE:PFE) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Daiwa downgraded Pfizer Inc. (NYSE:PFE) to Neutral from Outperform and set a $27 price target.Pfizer (PFE) Closes 2025 on Solid... Full story
Yahoo Finance • 10 days ago
$198.39 Bn Active Pharmaceutical Ingredients (API) Markets, 2030 by Synthesis (synthetic, Biotech), Potency (HPAPI), Product (mAbs, Hormones), Drug (OTC, Rx), Application (Diabetes, Oncology)
Company Logo The global active pharmaceutical ingredients (API) market is poised to reach USD 198.39 billion by 2030, witnessing a CAGR of 6.6% from USD 144.20 billion in 2025. The API market's growth is significantly driven by expanding... Full story
